News Releases

News Releases

December 5, 2019
MeiraGTx to Host Parkinson’s Disease R&D Day in New York
LONDON and NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc  (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a Parkinson’s disease-focused R&D Day on December 13, 2019 from 9:00-11:30 a.m. ET in New York .
November 26, 2019
MeiraGTx to Present at Upcoming Healthcare Conferences
LONDON and NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc  (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Evercore ISI 2 nd  Annual HealthCONx
November 7, 2019
MeiraGTx Reports Third Quarter 2019 Financial Results
LONDON and NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the quarter ended September 30, 2019 and provided an update on recent progress.
October 3, 2019
MeiraGTx to Present at Upcoming Scientific and Investor Conferences
LONDON and NEW YORK , Oct. 03, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the Company will present at the following upcoming events: 3rd Annual Chardan Genetic Medicines Conference in New York
August 8, 2019
MeiraGTx Announces Pricing of Public Offering of Ordinary Shares
LONDON and NEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the pricing of an underwritten public offering of 3,200,000 of its ordinary shares at a public offering price of $23.50 per
Displaying 1 - 10 of 20